Patent · US Active

Treatment of idiopathic pulmonary fibrosis

US11819494B2 · kind B2 · utility

3Cited by

0References

19Claims

0Family size

Assignee

VICORE PHARMA AB · SE

Inventors

Carl-Johan Dalsgaard · Stockholm, SE
Rohit Batta · Chino, US

Key dates

Filing date	Feb 25, 2022
Grant date	Nov 21, 2023
Priority date	—
Expiry date	Feb 25, 2042

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/4891
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

According to the invention there is provided a method of improving (e.g. restoring) function in a patient having idiopathic pulmonary fibrosis, which method comprises perorally administering a therapeutically-effective amount of N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide (C21), or a pharmaceutically acceptable salt thereof, to said patient. Said treatment is capable of treating said IPF in a therapeutic, including a curative, fashion.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.